AMG-208

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H17N5O2
Molecular Weight	383.4027
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=C(C=C1)C(OCC3=NN=C4C=CC(=NN34)C5=CC=CC=C5)=CC=N2

InChI

InChIKey=HEAIZQNMNCHNFD-UHFFFAOYSA-N

InChI=1S/C22H17N5O2/c1-28-16-7-8-17-19(13-16)23-12-11-20(17)29-14-22-25-24-21-10-9-18(26-27(21)22)15-5-3-2-4-6-15/h2-13H,14H2,1H3

HIDE SMILES / InChI

Molecular Formula	C22H17N5O2
Molecular Weight	383.4027
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18426196 | http://adisinsight.springer.com/drugs/800029397
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26155941

Amgen was developing AMG-208, a small molecule inhibitor of c-Met, for the treatment of cancer. AMG-208 shows the potent inhibition of kinase c-Met activity with IC50 of 9 nM in a cell-free assay. Besides, AMG-208 treatment also leads to the inhibition of HGF-mediated c-Met phosphorylation in PC3 cells with IC50 of 46 nM. AMG-208 showed evidence of antitumor activity, particularly in prostate cancer. On December 1, 2014 Amgen completed a phase I trial in solid tumours.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hepatocyte growth factor receptor 54 Target ID: CHEMBL3717 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18426196	Inhibitor 8297		9.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 592 Sources: https://clinicaltrials.gov/ct2/show/NCT00813384	Primary		Phase I 428	Unknown Approved Use Unknown
Prostate cancer 178 Sources: https://clinicaltrials.gov/ct2/show/NCT02420587	Primary		Withdrawn	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
18.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26155941	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:		AMG-208 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
245 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26155941	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:		AMG-208 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
45.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26155941	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:		AMG-208 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY111463	https://www.001chemical.com/chem/search?q=DY111463
1PlusChem LLC	1P0001RG	https://www.1pchem.com/search?query=1P0001RG
AK Scientific	Y0333	https://aksci.com/item_detail.php?cat=Y0333
Angene	AGN-PC-04SVHS	http://www.angenechemical.com/productshow/AGN-PC-04SVHS.html
ApexBio Technology	A1186	https://www.apexbt.com/catalogsearch/result/?q=A1186
Axon MedChem	1916	https://www.axonmedchem.com/product/1916
BLD Pharm	BD370490	http://www.bldpharm.com/search/Search.html?keyword=BD370490
BOC Sciences	1002304-34-8	http://www.bocsci.com/description.asp?cas=1002304-34-8
Chem Scene	CS-0185	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0185
ChemShuttle	104824	https://www.chemshuttle.com/catalogsearch/result/?q=104824
Lab Network	LN01342225	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01342225
Matrix Scientific	145218	http://www.matrixscientific.com/145218.html
MedChem Express	HY-12035	https://www.medchemexpress.com/search.html?q=HY-12035&ft=&fa=&fp=
MolPort	MolPort-016-633-199	https://www.molport.com/shop/molecule-link/MolPort-016-633-199
Molcore	MC111463	http://www.molcore.com/CatMC111463.html
Molnova	M10027	https://www.molnova.com/en/serch-list.html?keywords=M10027
MuseChem	I000077	https://www.musechem.com/product/I000077.html
ShangHai Biochempartner	BCP000051	http://www.biochempartner.com/search_BCP000051
ShangHai Biochempartner	BCP01384	http://www.biochempartner.com/search_BCP01384
TargetMol	T6260	https://www.targetmol.com/search?keyword=T6260
Toronto Research Chemicals	A576533	https://www.trc-canada.com/product-detail/?CatNum=A576533
eMolecules	32176561	https://orderbb.emolecules.com/search/#?query=32176561
eNovation Chemicals	D372416	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D372416&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-7012163781	https://mcule.com/MCULE-7012163781/

PubMed

Title	Date	PubMed
		252160567

Patents

Sample Use Guides

In Vivo Use Guide

Three to nine patients were enrolled into one of seven AMG-208 dose cohorts (25, 50, 100, 150, 200, 300, and 400 mg). Patients received AMG-208 orally on days 1 and days 4-28 once daily.

Route of Administration: Oral

In Vitro Use Guide

AMG-208 treatment leads to the inhibition of HGF-mediated c-Met phosphorylation in PC3 cells with IC50 of 46 nM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:35:03 GMT 2023` Edited by `admin` on `Sat Dec 16 05:35:03 GMT 2023`
Record UNII	Y2SR66P7VM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMG-208

Common Name

English

AMG 208

Common Name

English

4-((6-PHENYL-(1,2,4)TRIAZOLO(4,3-B)PYRIDAZIN-3-YL)METHOXY)-7-METHOXYQUINOLINE

Systematic Name

English

AMG208

Common Name

English

AMG 208 [WHO-DD]

Common Name

English

QUINOLINE, 7-METHOXY-4-((6-PHENYL-1,2,4-TRIAZOLO(4,3-B)PYRIDAZIN-3-YL)METHOXY)-

Systematic Name

English

Code System Code Type Description

PUBCHEM

24864821